Navigation Links
Hovione and Solvias Announce a Collaboration to Provide for Improved Drug Solubility
Date:11/28/2012

LISBON, Portugal, November 28, 2012 /PRNewswire/ --

Hovione and Solvias today announced the establishment of a collaboration focused on the development and GMP supply of pharmaceutical co-crystals. This strengthens Hovione's expertise and experience in overcoming drug delivery challenges and also the supply of GMP materials from phase I to commercial scale, with Solvias' excellence in solid state chemistry.

Hovione offers a series of innovative particle engineering technologies focused on amorphous solid dispersions, crystal design and reduction and control of particle size. The collaboration provides Hovione access to Solvias' co-crystallization expertise and capabilities, thus reinforcing and complementing the crystal design solutions to overcome poor bioavailability and other drug delivery challenges. Solvias continues its strategy of partnering to enhance access to its solid-state solutions.

"We are delighted to announce this collaboration with Solvias increasing the breadth of drug delivery solutions through our Particle Design offering. Solvias has a tremendous reputation for science, quality and expertise in crystal design for improved drug performance. This agreement reinforces our strategy of combining strengths with innovative companies to allow our customers a seamless and integrated approach to their drug delivery challenges." said Dr. Colin Minchom, Hovione's Vice President of Particle Design.

Dr. Martina Diekmann, Solvias' Global Head of Business Development Analytics commented "Solvias is delighted to work with Hovione.  In establishing this agreement with Hovione, we are able to generate added value for our customers and to help them solving their drug delivery requirements."

About Hovione. Hovione is a global company with over 50 years' experience in Active Pharmaceutical Ingredient and Drug Product Intermediate development and compliant manufacture. With four FDA inspected sites in the U.S., China, Ireland, and Portugal, the company focuses on the most demanding customers in the most regulated markets. Hovione offers integrated API, particle design, formulation development and GMP manufacturing. In the inhalation area, Hovione is the only independent company offering such a broad range of services.

About Solvias. Solvias is a privately held company located in Basel, Switzerland, with recognized high standards as a service provider to the pharmaceutical industry with full cGMP compliance (FDA, Swissmedic). With over 250 highly qualified employees, Solvias supports the research and development of new drug substances and drug products for pharmaceutical and life science companies worldwide.Solvias'profound know-how for analytical and chemical development, its experience and proven track record include:  Analytical Services for small molecules and biopharmaceuticals,;
Solid-State Services: Polymorphism, Salts, and Crystallization; Chemical Development and API Manufacturing up to phase II; Catalysis; Process Analytical Technology.

For more information about Hovione, please visit http://www.hovione.com or contact Marketing & Communication,  Isabel Pina, +351-21-982-9362, e-mail: ipina@hovione.com.

For media requests, please contact: Tim Senn, Marketing Communication Manager at tim.senn@solvias.com or +41-61-845-61-41


'/>"/>
SOURCE Hovione
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Robbins Umeda LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Abiomed, Inc.
2. Echo Therapeutics Announces Proposed Public Offering
3. Landauer, Inc. Sets Date And Time For Announcement Of Fiscal Fourth Quarter And Full Year 2012 Results
4. Alere Inc. Announces Offering of $450 Million of Senior Notes
5. Perrigo Announces FDA Final Approval Of Betamethasone Valerate Foam 0.12%
6. SHAREHOLDER ALERT: Morgan & Morgan announces an investigation of Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) and whether senior management and the board of directors violated fiduciary duties owed to Vertex shareholders.
7. Regeneron Announces Presentation at the Deutsche Bank 2012 dbAccess BioFEST
8. Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2012 Fourth Quarter Results And Provides Clinical Study Update
9. Golden Meditech Announces 2012 / 2013 Interim Results
10. TriReme Announces a New Round of Financing Totalling US$18 Million
11. Baby Quasar announces the launch of its next-gen skin care tool, Clear Rayz, for the treatment of acne
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... , Dec. 9, 2016 aTyr Pharma, Inc. (Nasdaq: ... development of Physiocrine-based therapeutics to address severe, rare diseases, today announced ... upcoming BMO Prescriptions for Success Healthcare Conference at the InterContinental Barclay ... December 14, 2016, at 4:20 p.m. ET. About ... ...
(Date:12/9/2016)... , Dec. 9, 2016  Forge Therapeutics, ... AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) ... ,LpxC, for the treatment of bacterial infections including ... been recognized as an attractive antibacterial target for ... lack of suitable chemical starting points has hampered ...
(Date:12/8/2016)... 8, 2016  The global biosurgery market is expected ... forecast period of 2016 to 2021. The market is ... USD 18.21 billion in 2016. The market is primarily ... sports related injuries and spinal problems, increasing clearance of ... effective blood loss management. In this report, ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... 2016 , ... MEDI+SIGN®, a provider of fully-automated patient monitoring ... for Emergency Departments (ED) has been added to their portfolio. Housed in a ... and with a simplified pallet of information available to the patient, the Digital ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Compensation Research Institute (WCRI) officially opened registration today for its 33rd Annual ... in Boston, MA . , The theme of the conference is “Persistent Challenges ...
(Date:12/8/2016)... ... 2016 , ... CURE Media Group, the nation’s leading digital and print media ... Lung Cancer in efforts to combat lung cancer, announced CURE Media Group President Michael ... Media Group is honored to team up with Upstage Lung Cancer in order to ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... version gives development continuity to its innovative Unified Instance Manager architecture, meeting ... In addition, this new version optimizes the unattended auto-dialing system without agents, ...
(Date:12/8/2016)... Peachtree City, Ga (PRWEB) , ... December 08, ... ... and moving as soon after surgery as possible. With this in mind, SIGVARIS ... vein thrombosis (DVT or blood clot) during bed rest and provide the benefits ...
Breaking Medicine News(10 mins):